Management of diarrhea induced by tumors or cancer therapy.
Diarrhea is a common event in the clinical history of cancer patients. It can be caused by the presence of tumor or it can be a side effect of treatment. The latter problem is occurring more often because new drugs (CPT-11) or drug combinations (fluorouracil plus interferon or leucovorin) have diarrhea as the dose-limiting toxicity. The clinical use of octreotide, a long-acting somatostatin analogue, seemed to demonstrate an improvement in most diarrheal states induced by tumors (endocrine tumors) or by treatments (short bowel syndrome; chemotherapy-induced diarrhea).
Cascinu
S
S
Servizio di Oncologia Medica, Ospedale di Pesaro, Italy.
D000930:Antidiarrheals / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000009:adverse effects*; D016026:Bone Marrow Transplantation / Q000009:adverse effects; D003110:Colonic Neoplasms / Q000150:complications; D003967:Diarrhea / Q000209:etiology / Q000517:prevention & control / Q000628:therapy*; D005260:Female; D006801:Humans; D008297:Male; D009369:Neoplasms / Q000150:complications* / Q000628:therapy; D015282:Octreotide / Q000627:therapeutic use; D011878:Radiotherapy / Q000009:adverse effects*
D000930:Antidiarrheals; D000970:Antineoplastic Agents; D015282:Octreotide